Paras Healthcare's IPO entered its second day of bidding on Thursday, October 22, amid a muted response from investors. In the grey market, the issue is commanding a premium of around 4%, indicating expectations of a modest listing gain over the issue price.

On Day 1, the IPO was subscribed 15% overall against 1.20 crore shares on offer. The retail individual investor (RII) portion was subscribed 69% against 21.96 lakh shares reserved for the category.

The public issue opened on October 21, 2026, and will remain open for subscription until October 23, giving investors a three-day bidding window.

The Rs 1,450 crore IPO comprises a fresh issue of 72.15 lakh shares worth Rs 500 crore and an offer for sale (OFS) of 1.37 crore shares aggregating to Rs 950 crore.

Paras Healthcare has fixed the IPO price band at Rs 660–Rs 693 per share, with a lot size of 21 shares. At the upper end of the price band, retail investors need to invest a minimum of Rs 14,553 to apply for one lot.

The basis of allotment is expected to be finalised on October 26, while the shares are tentatively scheduled to list on the BSE and NSE on October 28, 2026.

JM Financial Ltd., BofA Securities India Ltd. and Nuvama Wealth Management Ltd. are the book-running lead managers for the issue, while MUFG Intime India Pvt. Ltd. is the registrar.

Paras Healthcare IPO: Anchor investor details

Paras Healthcare raised Rs 652.5 crore from anchor investors on October 19, a day before the IPO opened for public subscription. The anchor investors included Abu Dhabi Investment Authority, BlackRock Global Funds, Eastspring Investments, Government Pension Fund Global, Natixis International Funds, Integrated Core Strategies (Asia) and Citigroup Global.

Paras Healthcare IPO Subscription Status

Paras Healthcare's IPO received a muted response on the first day of bidding, with the issue subscribed 15% overall against 1.20 crore shares on offer.

The retail individual investor (RII) portion was subscribed 69% against 21.96 lakh shares reserved for the category. The non-institutional investor (NII) segment saw a subscription of 8% against 32.95 lakh shares allocated to the category.

Meanwhile, the qualified institutional buyer (QIB) portion had yet to receive any bids against the 65.90 lakh shares reserved for the segment.

Paras Healthcare IPO GMP Today

Paras Healthcare IPO is commanding a grey market premium (GMP) of Rs 25 per share, translating into a premium of around 4% over the upper end of the issue price band of Rs 693. Based on the prevailing GMP, the estimated listing price works out to approximately Rs 718 per share.

IPO Objects of the Issue

The company plans to utilise Rs 320.90 crore from the net proceeds of the IPO to prepay or repay, either fully or partially, certain outstanding borrowings availed by the company. Additionally, Rs 54.10 crore will be invested in its wholly owned subsidiary, PMHPL, which operates a hospital in Srinagar, to facilitate the full or partial repayment or prepayment of its outstanding borrowings.

The remaining proceeds will be allocated towards general corporate purposes. Of the total IPO proceeds of Rs 375 crore, the primary objective is to reduce the company's debt burden, strengthen its financial position and support its overall corporate requirements.

Paras Healthcare Ltd. reported a 24% year-on-year increase in total income to Rs 1,629 crore in FY26, compared with Rs 1,314 crore in FY25. The company also turned profitable, posting a profit after tax (PAT) of Rs 44 crore in FY26, against a loss of Rs 58 crore in the previous financial year.

Incorporated in1987, Paras Healthcare Limited is a leading clinical specialty-led hospital platform providing tertiary and quaternary healthcare services across North India, Bihar, and Jharkhand under the "Paras Health" brand. The company operates eight hospitals with an aggregate bed capacity of 2,211 beds across Gurugram, Panchkula, Patna, Darbhanga, Kanpur, Udaipur, Ranchi, and Srinagar as of June 30, 2026.

It specializes in cardiac sciences, oncology, neurosciences, gastro sciences, orthopedics & sports injury, and renal sciences (CONGOR specialties), which contributed 75.30% of revenue in Fiscal 2026. Paras Healthcare has over 20 years of operating history and follows a balanced growth strategy through mature, emerging, and new hospitals. The company plans to expand its network with a 300-bed hospital in Gurugram and a 500-bed hospital in Ludhiana, increasing total capacity to 3,011 beds by March 2028. As of March 31, 2026, it had 4,670 employees, including 1,084 doctors and 1,937 nurses.

Disclaimer: The views/recommendations mentioned in this article, wherever applicable, are those of the respective SEBI-registered Research Analyst/brokerage and have been reproduced/reported with due attribution. They should not be construed as the views or recommendations of The Economic Times Digital or the journalist. Readers are advised to consider the original research report and make their investment decisions based on their own assessment. Brokerage disclaimers here